BioNexus Gene Lab Corp: Form 10-Q for the period ended Jun 30, 2019
Filed with the SEC on Aug 9, 2019 and accepted by EDGAR at Aug 9, 2019, 19:22 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-04-01 to 2019-06-30 | $21.6k | us-gaap:Revenues |
| Revenue | 6 months2019-01-01 to 2019-06-30 | $49.7k | us-gaap:Revenues |
| Cost of revenue | 3 months2019-04-01 to 2019-06-30 | $17.0k | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2019-01-01 to 2019-06-30 | $35.8k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-04-01 to 2019-06-30 | $4.6k | us-gaap:GrossProfit |
| Gross profit | 6 months2019-01-01 to 2019-06-30 | $13.9k | us-gaap:GrossProfit |
| Operating income | 3 months2019-04-01 to 2019-06-30 | −$69.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2019-01-01 to 2019-06-30 | −$129.4k | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2019-04-01 to 2019-06-30 | $1.2k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2019-01-01 to 2019-06-30 | $2.4k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-04-01 to 2019-06-30 | −$70.4k | us-gaap:NetIncomeLoss |
| Net income | 6 months2019-01-01 to 2019-06-30 | −$131.9k | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2019-01-01 to 2019-06-30 | −$101.5k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2019-01-01 to 2019-06-30 | $9.2k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2019-06-30 | $1.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-06-30 | $1.5m | us-gaap:Assets |
| Current liabilities | At period end2019-06-30 | $64.2k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-06-30 | $123.3k | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-06-30 | $1.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001551163-19-000195. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.